Q32 Bio (QTTB) EBITDA Margin (2018 - 2023)
Q32 Bio's (QTTB) quarterly EBITDA Margin came in at 1897.72% in Q4 2023, up 619872.0% year-on-year from N/an in Q4 2022, and up 552.41% quarter-over-quarter from 419.47% in Q3 2023.
Q32 Bio (QTTB) EBITDA Margin (2018 - 2023) Analysis & Trends
Q32 Bio's EBITDA Margin history runs 6 years deep, the most recent figure standing at 1897.72% for Q4 2023.
- On a quarterly basis, EBITDA Margin rose 619872.0% year-over-year to 1897.72% in Q4 2023; TTM through Sep 2024 was 5690.07%, a 633616.0% increase from a year earlier, with the FY2025 full-year figure at 31.45%, changed N/A from the prior year.
- EBITDA Margin advanced to 1897.72% in Q4 2023 per QTTB's latest filing, from 419.47% in the prior quarter.
- Across five years, EBITDA Margin topped out at 1897.72% in Q4 2023 and bottomed at 9304.81% in Q1 2019.
- The 5-year median for EBITDA Margin is 4145.07% (2021), against an average of 3582.2%.
- Across the five-year window, EBITDA Margin sank 835743 bps in 2019 and soared 620233 bps in 2021, its largest moves.
- Year by year, EBITDA Margin stood at 4539.79% in 2019, then soared by 33 bps to 3041.02% in 2020, then sank by 38 bps to 4192.64% in 2021, then decreased by 3 bps to 4301.0% in 2022, then soared by 144 bps to 1897.72% in 2023.
- Per Business Quant, the three latest QTTB EBITDA Margin figures stand at 1897.72% (Q4 2023), 419.47% (Q3 2023), and 226.99% (Q2 2023).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Q32 Bio | 225.00 Mn | 174.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 1,897.72% |
| Sep 30, 2023 | -419.47% |
| Jun 30, 2023 | -226.99% |
| Mar 31, 2023 | -250.19% |
| Dec 31, 2022 | -4,301.00% |
| Sep 30, 2022 | -4,097.51% |
| Jun 30, 2022 | -3,529.55% |
| Mar 31, 2022 | -4,690.52% |
| Dec 31, 2021 | -4,192.64% |
| Sep 30, 2021 | -1,828.32% |
| Jun 30, 2021 | -1,396.98% |
| Mar 31, 2021 | -3.79% |
| Dec 31, 2020 | -3,041.02% |
| Sep 30, 2020 | -4,986.42% |
| Jun 30, 2020 | -6,295.77% |
| Mar 31, 2020 | -6,206.12% |
| Dec 31, 2019 | -4,539.79% |
| Sep 30, 2019 | -7,094.78% |
| Jun 30, 2019 | -7,135.97% |
| Mar 31, 2019 | -9,304.81% |